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prostate biopsy between January 2006 and 
June 2007, we determined the overall cancer 
detection rate in all patients and in 
subgroups based on prostate specific 
antigen level, digital rectal examination, and 
indication for biopsy. We assessed the 
pathological significance of cancer detected, 










tumour volume in the prostatectomy 
specimen. We also evaluated the 
concordance in Gleason score between the 




Cancer was detected in 50 (35.7%) of 
the 140 patients biopsied, including 39 
(47.6%) with no previous biopsies. Of 23 
prostatectomy specimens, 20 (87%) had 
pathologically significant disease. The biopsy 
predicted the prostatectomy Gleason score 
in 12 patients (52%), overestimated in two 
(9%), underestimated in eight (35%), and 





Template-guided biopsy potentially 
produces a higher cancer detection rate 
and more accurate assessment of grade. 
Prostatectomy specimens did not have a 




prostatic neoplasms, diagnosis, biopsy, 
sampling 
Study Type – Diagnostic 
(non-consecutive review) 




To explore the ability of a novel transrectal 





Envisioneering Medical Technologies, St. 
Louis MO) that creates a three-dimensional 
map of the prostate and calculates an 
optimal biopsy scheme, to accurately sample 
the prostate and define the true extent of 
disease, as standard TRUS-guided prostate 
biopsy relies on the operator to distribute the 
biopsy sites, often resulting in under- and 




In a multicentre retrospective chart review 
evaluating patients who had a TargetScan 
INTRODUCTION
 
Prostate cancer is the most common solid 
malignancy in men, with an estimated 
218 890 new cases and 27 050 deaths in 2007 
[1]. Screening with PSA level and a DRE has 
led to an increase in detection, and decrease 
in disease-specific mortality [2]. TRUS-guided 
prostate biopsy has been the standard 
method for diagnosing prostate carcinoma, 
but has several potential shortcomings.
False-negative rates remain of concern, with 





30% of clinically significant 
prostate cancer [3], and a high percentage 
(23%) of cancers missed are high-grade 
(Gleason 8 and 9) [4]. In addition, among 
those in whom prostate cancer is detected, 
the manner in which the biopsy cores are 
obtained makes it difficult to precisely 
characterize the true extent of the tumour. 
Standard manually guided biopsy sampling 
might make Gleason scores or needle-core 
volumes imprecise. As both correlate with 
outcome after therapy [5], an accurate 
assessment of tumour characteristics is 
critical for counselling patients and guiding 
therapy.
The primary technique to minimize false-
negative rates of TRUS-guided biopsy has 
been to take more cores per biopsy session, 
and include more laterally placed biopsy cores 
to sample the peripheral zone [6–8]. While 
this has decreased the under-sampling of 
tumours, it has associated morbidity [9,10], 
which increases as more cores are taken 
during biopsies [11]. Also there is increasing 
concern that patients are being diagnosed 
with clinically insignificant disease [12].
Given these limitations of contemporary 
biopsy schemes, there is a motivation to 
develop an improved instrument or diagnostic 
method that has a high detection rate for 
prostate cancer within the ‘window of 
opportunity’ for treatment, but minimizes the 
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detection of clinically insignificant disease. 
Recently, there have been many new 
techniques for prostate cancer diagnosis, 
including the use of ultrasonographic 
contrast agents, colour Doppler, power 






 system (Envisioneering 
Medical Technologies, St. Louis, MO, USA) is a 
novel TRUS device that allows accurate needle 
placement within a template. First, a three-
dimensional map of the prostate is created; 
then a computer algorithm calculates an 
optimum biopsy scheme using the measured 
dimensions of the prostate. The system then 
uses a fixed template that allows the 
physician to biopsy the prostate at specific 
locations. The instrument can be used for 12-
core template biopsy or for targeted and 
saturation biopsy if indicated. The instrument 
can be used to target the same region of the 
prostate in the future if needed, which is 
particularly useful in patients with suspicious 
histology, such as atypia, on initial biopsy.
The aim of the present study was to describe 
a multicentre experience with the TargetScan 
template-guided biopsy system, and to show 
how improved precision potentially translates 
into a higher cancer detection rate without 





In a multicentre retrospective chart review, 
after obtaining institutional review board 
approval at all sites, we retrospectively 
reviewed the clinical and pathological data of 
199 consecutive patients at Washington 
University, Duke University, and University of 
Michigan who had a prostate biopsy using the 
TargetScan system between January 2006 and 
June 2007. We excluded patients who did not 
have PSA or DRE findings recorded (two), 
those who had had a previous diagnosis of 
prostate cancer (13), and those who were 
enrolled in a prospective evaluation of the 
device (44); the final study population 
comprised 140 patients.
The data extracted from charts included the 
most recent serum PSA level, DRE findings, 
number of previous biopsies, pathology from 
biopsies, and, if performed, surgical pathology 
from the radical prostatectomy (RP). 
Pathological variables recorded were Gleason 
score, volume of disease, margin status, 
invasion of seminal vesicles, lymph node 
status, extracapsular extension and perineural 
invasion. Pathological information was 
collected from surgical pathology reports, and 
clinical information, including PSA and DRE 
findings, were collected primarily from a form 
completed by the treating physician on 
the day of the procedure. Other clinical 
information, including patient age and 
number of previous biopsies, were obtained 
from all other documents available in 
patients’ medical records.
The TargetScan system is a commercially 
available TRUS template-guided prostate 
biopsy instrument approved by the USA Food 
and Drug Administration. The instrument has 
the following components: An endorectal 
ultrasound probe, which once inserted in the 
rectum remains fixed for the entire 
procedure; an ultrasound transducer which 
moves within the probe to provide, within 
1–2 min, a scan of the prostate created in 
1-mm increments, thus increasing image 
precision; a PC-based digital hardware and 
software system for image planning, data 
storage and retrieval; a novel single use 
flexible 18 G Nitinol biopsy needle which is 
inserted into the biopsy guide parallel to the 




, thus maximally 
sampling the peripheral zone.
Using the TargetScan is an office-based 
procedure, performed under local anaesthesia 
with patients in the dorsal lithotomy position. 
The probe is inserted transrectally; the 
ultrasonograms are taken and can be 
displayed simultaneously in transverse and 
sagittal planes, and reconstructed in three 
dimensions. While the instrument has the 
capacity for targeted biopsy and saturation 
biopsy, in our experience, a 12-core template 
biopsy was used. The system plans a 12-core 
biopsy using the following algorithm: from 
the sagittal view, three planes that are equally 
spaced with respect to prostate apex and base 
are calculated; at each of the three pre-
selected transverse planes, the left and right 
edges of the prostate are marked and four 
locations are calculated for each plane (Fig. 1). 
The position of the biopsy guide is quantified 
using depth of insertion (cm from the apex) 
and rotational variables (degrees from the 12 
o’clock position). The precise location from 
which samples were taken is stored using the 
two co-ordinates, and is included in a printed 




10 min for 
a 12-core template biopsy.
We determined the overall cancer detection 
rate in all patients requiring biopsy, and then 
in various subgroups based on serum PSA 
level, DRE findings, and the indication for 
biopsy. We assessed the pathological 
significance of cancer detected by evaluating 
surgical pathology reports in patients who 
had RP. We defined pathological significance 














The study comprised 140 men (median age 
64 years, range 46–85); 107 received care at 
Washington University, 22 at Duke University, 
and 11 at the University of Michigan. All 
patients had a DRE and serum PSA testing. 
The median (range) serum PSA level in all 




Biopsy Scheme – A) Sagital view 
demonstrates that needles are placed uniformly 
from apex to base.  B) Transverse view demonstrates 
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patients (41.4%) had had previous six- to 12-
core biopsies using the standard technique.
The template biopsy detected prostate cancer 
in 50 of the 140 patients (35.7%) and 39 of 82 
(48%) having their first biopsy. The cancer 
detection rate in subgroups based on the 
indication for biopsy is shown in Table 1, 
which also shows the percentage of cancer-
positive biopsies based on the number of 
previous biopsies. Table 2 shows the prostate 
cancer detection rate in groups stratified by 
PSA level and DRE findings.
In all, 23 of 50 (46%) patients had a RP; the 
median (range) Gleason sum score was 7
(6–9) and median volume of disease was 
10 (1–30)%. Of the 23 patients, nine (39%) 
had a positive margin, two (9%) had invasion 
of the seminal vesicle, none had positive 
lymph nodes, seven (30%) had extracapsular 
extension and 13 (57%) had perineural 
invasion. Based on the definition of 










20% tumour volume), only 
three patients (13%) were found to have 
pathologically insignificant disease. 
Comparing the Gleason score from the biopsy 
cores with that from the RP specimen showed 
concordance in 12 of the 23 patients (52%), 
over-grading in two (9%), under-grading 
in eight (35%), and in one patient (4%), 
insufficient tissue was obtained on biopsy to 
assign a Gleason score, but the patient was 




Prostate cancer is the most common 
malignancy in men [1]. Given the need to 
detect the cancer during the ‘window of 
opportunity’ for treatment, but also the 
concurrent need to minimize the detection of 
clinically and pathologically insignificant 
disease, there has been an increasing search 
for newer techniques to satisfy these 
demands. In our experience with the 
TargetScan device, 48% of patients having 
their first biopsy and 36% of the entire group 
were positive for prostate cancer. This is 
higher than has been observed with 
traditional TRUS-guided 12-core biopsy, at 





detected cancer in 139 of 375 (37.1%) of all 
patients undergoing biopsy, and 112 of 264 









 [16], after 
evaluating patients having their first biopsy, 
found a cancer detection rate of 44.4% and 
38.7%, respectively; in both studies, patients 
had a 12-core biopsy. Some studies have 
reported markedly lower cancer detection 




 [17] reported a 
cancer detection rate of only 27% in their 
entire group of patients having a 12-core 
biopsy. While the present study implies that 
the TargetScan improves detection rates, it is 
difficult to compare cancer detection rates 
between these studies, given that there are 
almost certainly differences in the 
populations studied.
Not surprisingly, when we assessed subgroups 
with different indications for biopsy (Table 1), 
the highest cancer detection rate was in those 
having a biopsy for both an elevated PSA level 
and an abnormal DRE, followed by the group 
biopsied for an elevated PSA level only, then 
the group biopsied for abnormal DRE findings 
only, and finally those biopsied because they 
had a history of pathological atypia on 
previous biopsy. As shown in Table 2, when 
groups were stratified by both PSA and DRE 
findings, the highest cancer detection rate 
was in the subgroup with a positive DRE and 




10 ng/mL. As shown in Table 2, 
as the PSA level increased, the rate of cancer 
detection increased both in those with a 
positive and those with a negative DRE. 
Overall, patients with a positive DRE also had 
a higher rate of cancer detection than those 
with a negative DRE.
In the present patients only three of the 23 
(13%) who had a RP had pathologically 
insignificant disease. Using a slightly different 




 [18] found that 16% of 157 men who 
had a RP after conventional biopsy for clinical 
stage T1c prostate cancer had pathologically 
insignificant disease. They defined 









0.2 mL and tumour 
confined to the prostate. In their study, the 
number of biopsy cores was not standardized, 
but had a mean and median of five cores per 
patient. Given that more cores were obtained 
in the present study (12), more insignificant 
disease would be expected to be detected, 
yet we detected a smaller percentage of 
insignificant disease. This might reflect that 
the conventional technique over-samples 




The cancer detection rate in subgroups (two patients did not have reason for biopsy recorded) 












Elevated PSA level only 35 102 34.3





 abnormal DRE 9 12 69
History of atypia on previous biopsy 1 14 1/14
Biopsy number
First 39 82 47.6
Second 6 23 27.3
Third 3 14 3/14
Fourth 1 8 1/8
Fifth 0 8 0
Sixth 1 4 1/4




Prostate cancer detection rates stratified by PSA level and DRE findings
 
DRE














Negative 1/7 3/17 (18) 22/68 (32) 6/12 32/104 (30.8)
Positive 2/9 2/3 12/22 (55) 2/2 18/36 (50)
Total 3/16 (19) 5/20 (25) 34/90 (38) 8/14 50/140 (36)
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was sampled repeatedly, while the template 
technique ensures that each region is 
sampled only once. An alternative reason for 
the difference might simply be that the 
present study only examined 23 patients who 
had RP and a larger study would show no 
difference from previous work.
We assessed the ability of template-guided 
biopsy to predict the RP Gleason score, and 
found that it led to accurate grading in most 
patients (52%), over-grading in two (9%), 
under-grading in eight (35%), and in one 
patient with Gleason 6 disease there was 
insufficient malignant tissue obtained on 





[19] studied 205 men who had had a 
traditional extended biopsy before RP, and 
found a concordance rate of 68%, under-
grading by biopsy in 17% and over-grading in 
15%. Again perhaps, the concordance rate in 
the present study might be lower because 





 comparison of the TargetScan 
device and conventional biopsy showed that 
the template-guided biopsy more accurately 
predicted RP Gleason score than traditional 
TRUS biopsy [3].
This device has various potential advantages 
over traditional TRUS-guided biopsy. As the 
probe remains fixed during the procedure, 
it minimizes image distortion due to probe 
movement against the prostate. Its capacity 
to map the prostate and to record the exact 
location of each core has several important 
potential advantages. For patients undergoing 
second biopsies, the pattern can be altered 
to examine under-sampled regions and 
suspicious locations can be precisely re-
biopsied. Last, the instrument can be used for 
planned template biopsy, targeted biopsy and 
saturation biopsy.
While the TargetScan system has shown 
several improvements over traditional TRUS-
guided biopsy, there are several advances that 
could further improve its utility for prostate 
cancer diagnosis in the future. The current 
biopsy protocol arrays 12 cores geometrically 
throughout the prostate, without 
consideration for the non-random 
distribution of cancer throughout the 
prostate, or the need for more cores in larger 
prostates [20]. Alternative algorithms that 
adjust for the non-random distribution of 
tumour within the prostate, and alter the 
number of cores based on gland volume, 
could improve the diagnostic ability.
There are several limitations to the present 
study. It was a retrospective chart review and 
there is no direct comparison between this 
device and traditional TRUS-guided biopsy. 
We attempted to minimize the bias of a 
retrospective study by collecting objective 
data except for the DRE findings, which were 
primarily collected from a document 
completed by the treating physician at the 
time of biopsy. Our definition of tumour 
volume was a percentage and not an absolute 
number. This is again due to the retrospective 
nature of the analysis. Prostate tumour 
volumes at our institutions are reported in 
this manner. However, a 20% tumour volume 
for a 20 g prostate would correspond to 4 g of 
cancer, which exceeds a volume of 0.5 mL. We 
therefore think that the 20% reference point 
is a conservative estimate of low tumour 
volume.
In conclusion, traditional TRUS-guided 
prostate biopsy technique imprecisely locates 
the biopsy sites and as a result might not 
accurately describe the size, location and 
grade of the tumour, all of which are 
important in determining the optimum 
treatment for patients diagnosed with 
prostate cancer. Transrectal template biopsy 
offers several advantages over the traditional 
biopsy, including the ability to uniformly 
distribute biopsies throughout the prostate 
and record the location from which biopsy 
cores were taken, allowing re-biopsy of 
specific locations of interest in the future. We 
have shown that the precision of a template-
guided approach potentially leads to higher 
cancer detection rates, without increasing the 
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prostate cancer diagnosis – correlation 
















 Transrectal ultrasound-guided 
biopsy of prostate voxels identified as 
suspicious of malignancy on three-
dimensional (1)H MR spectroscopic 
imaging in patients with abnormal digital 
rectal examination or raised prostate 
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